Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Phase I Study of Seviteronel, a Selective CYP17 Lyase and Androgen Receptor Inhibitor, in Men with Castration-Resistant Prostate Cancer.

Gupta S, Nordquist LT, Fleming MT, Berry WR, Zhang J, Ervin SL, Eisner JR, Baskin-Bey ES, Shore ND.

Clin Cancer Res. 2018 Nov 1;24(21):5225-5232. doi: 10.1158/1078-0432.CCR-18-0564. Epub 2018 Jul 16.

PMID:
30012563
2.

eRADicAte: A Prospective Evaluation Combining Radium-223 Dichloride and Abiraterone Acetate Plus Prednisone in Patients With Castration-Resistant Prostate Cancer.

Shore ND, Tutrone RF, Mariados NF, Nordquist LT, Mehlhaff BA, Steere KJ, Harrelson SS.

Clin Genitourin Cancer. 2018 Apr;16(2):149-154. doi: 10.1016/j.clgc.2017.10.022. Epub 2017 Nov 7.

3.

Re-treatment with radium-223: first experience from an international, open-label, phase I/II study in patients with castration-resistant prostate cancer and bone metastases.

Sartor O, Heinrich D, Mariados N, Méndez Vidal MJ, Keizman D, Thellenberg Karlsson C, Peer A, Procopio G, Frank SJ, Pulkkanen K, Rosenbaum E, Severi S, Trigo Perez JM, Wagner V, Li R, Nordquist LT.

Ann Oncol. 2017 Oct 1;28(10):2464-2471. doi: 10.1093/annonc/mdx331.

4.

Androgen Receptor Modulation Optimized for Response (ARMOR) Phase I and II Studies: Galeterone for the Treatment of Castration-Resistant Prostate Cancer.

Montgomery B, Eisenberger MA, Rettig MB, Chu F, Pili R, Stephenson JJ, Vogelzang NJ, Koletsky AJ, Nordquist LT, Edenfield WJ, Mamlouk K, Ferrante KJ, Taplin ME.

Clin Cancer Res. 2016 Mar 15;22(6):1356-63. doi: 10.1158/1078-0432.CCR-15-1432. Epub 2015 Nov 2.

5.

Intermittent Chemotherapy as a Platform for Testing Novel Agents in Patients With Metastatic Castration-Resistant Prostate Cancer: A Department of Defense Prostate Cancer Clinical Trials Consortium Randomized Phase II Trial of Intermittent Docetaxel With Prednisone With or Without Maintenance GM-CSF.

Aggarwal RR, Beer TM, Weinberg VK, Higano C, Taplin ME, Ryan CJ, Lin AM, Alumkal J, Graff JN, Nordquist LT, Herrera I, Small EJ.

Clin Genitourin Cancer. 2015 Jun;13(3):e191-8. doi: 10.1016/j.clgc.2014.12.004. Epub 2014 Dec 9.

PMID:
25557266
6.

Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer.

Scher HI, Jia X, Chi K, de Wit R, Berry WR, Albers P, Henick B, Waterhouse D, Ruether DJ, Rosen PJ, Meluch AA, Nordquist LT, Venner PM, Heidenreich A, Chu L, Heller G.

J Clin Oncol. 2011 Jun 1;29(16):2191-8. doi: 10.1200/JCO.2010.32.8815. Epub 2011 Apr 11.

PMID:
21483004
7.

Improved survival in never-smokers vs current smokers with primary adenocarcinoma of the lung.

Nordquist LT, Simon GR, Cantor A, Alberts WM, Bepler G.

Chest. 2004 Aug;126(2):347-51.

PMID:
15302716
8.

DNA vaccines: an active immunization strategy for prostate cancer.

Wolchok JD, Gregor PD, Nordquist LT, Slovin SF, Scher HI.

Semin Oncol. 2003 Oct;30(5):659-66. Review.

PMID:
14571413
9.

Octreotide for gastrointestinal bleeding of obscure origin in an anticoagulated patient.

Nordquist LT, Wallach PM.

Dig Dis Sci. 2002 Jul;47(7):1514-5. No abstract available.

PMID:
12141810
10.

IgM Myeloma: An IgM Gammopathy Distinct from Waldenstrom's Macroglobulinemia.

Nordquist LT, Saba HI, Moscinski LC.

Hematology. 2001;6(1):53-8. doi: 10.1080/10245332.2001.11746553.

PMID:
27419604
11.

The hydration of the cornea. I. The transport of water from the cornea.

HARRIS JE, NORDQUIST LT.

Am J Ophthalmol. 1955 Nov;40(5 Pt 2):100-10. No abstract available.

PMID:
13268557
12.

Transport of glucose across the lens surfaces.

HARRIS JE, HAUSCHILDT JD, NORDQUIST LT.

Am J Ophthalmol. 1955 Feb;39(2 Pt 2):161-9. No abstract available.

PMID:
13228561
13.

Changes in the phosphate fractions of the lens under various conditions which influence cation transport.

HAUSCHILDT JD, HARRIS JE, NORDQUIST LT.

Am J Ophthalmol. 1955 Feb;39(2 Pt 2):155-60. No abstract available.

PMID:
13228560
14.

Lens metabolism as studied with the reversible cation shift. II. The effect of oxygen and glutamic acid.

HARRIS JE, HAUSCHILDT JD, NORDQUIST LT.

Am J Ophthalmol. 1954 Jul;38(1:2):148-51. No abstract available.

PMID:
13180628
15.

Lens metabolism as studied with the reversible cation shift. I. The role of glucose.

HARRIS JE, HAUSCHILDT JD, NORDQUIST LT.

Am J Ophthalmol. 1954 Jul;38(1:2):141-7. No abstract available.

PMID:
13180627

Supplemental Content

Loading ...
Support Center